{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:03:40Z","timestamp":1784901820438,"version":"3.55.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Scabies is a common problem in dermatology clinics, with an increasing burden in long-term care hospitals (LTCHs). Recent guidelines recognize both topical 5% permethrin and oral ivermectin as first-line treatment options for noncrusted scabies, whereas combination therapy is primarily recommended for crusted scabies. Management in routine practice remains challenging, particularly in patients with a heavier infestation, and evidence supporting combination strategies in noncrusted scabies remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate real-world microscopic treatment outcomes of oral ivermectin plus topical permethrin compared with permethrin monotherapy, including time to microscopic cure and microscopic persistence at weeks 2 and 4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of 429 outpatients with microscopically confirmed noncrusted scabies at a single Korean centre (2018\u201325). Patients received weekly topical permethrin plus oral ivermectin (200\u2005\u00b5g kg\u20131) (n = 204) or topical permethrin alone (n = 225) according to routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Time to microscopic cure was shorter with combination therapy than with monotherapy [mean 2.10 (SD 0.90) vs. 2.31 (SD 1.09) weeks, P = 0.03]. At week 2, microscopic persistence occurred in 30.4% (62\/204) of the combination group and 35.1% (79\/225) of the monotherapy group (P = 0.35). By week 4, persistent positivity occurred only in the monotherapy group [0% (0\/204) vs. 3.1% (7\/225), P = 0.02].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a real-world outpatient setting, ivermectin\u2013permethrin combination therapy was associated with earlier microscopic clearance than permethrin monotherapy. These findings suggest that combination therapy may be considered in selected patients with a heavier infestation or in settings where rapid parasitological clearance is a priority.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag113","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:44:02Z","timestamp":1772714642000},"page":"1442-1448","source":"Crossref","is-referenced-by-count":0,"title":["Microscopic clearance with ivermectin\u2013permethrin combination vs. permethrin alone in noncrusted scabies: a retrospective cohort study"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4885-3576","authenticated-orcid":false,"given":"Ye Ji","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Dermatology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine , Seoul ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine , Seoul ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Chul","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine , Seoul ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Seok","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine , Seoul ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Woo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine , Seoul ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"2026072409170814900_llag113-B1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jaad.2019.05.109","article-title":"Ectoparasites: scabies","volume":"82","author":"Thomas","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026072409170814900_llag113-B2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3855\/jidc.15222","article-title":"Scabies: update on treatment and efforts for prevention and control in highly endemic settings","volume":"16","author":"Widaty","year":"2022","journal-title":"J Infect Dev Ctries"},{"key":"2026072409170814900_llag113-B3","author":"World Health Organization"},{"key":"2026072409170814900_llag113-B4"},{"key":"2026072409170814900_llag113-B5","author":"Centers for Disease Control and Prevention. Clinical care of scabies"},{"key":"2026072409170814900_llag113-B6","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/09564624251321264","article-title":"British Association for Sexual Health and HIV national guideline on the management of scabies in adults 2025","volume":"36","author":"Morris","year":"2025","journal-title":"Int J STD AIDS"},{"key":"2026072409170814900_llag113-B7","doi-asserted-by":"crossref","first-page":"e0005920","DOI":"10.1371\/journal.pntd.0005920","article-title":"Scabies in the age of increasing drug resistance","volume":"11","author":"Khalil","year":"2017","journal-title":"PLOS Negl Trop Dis"},{"key":"2026072409170814900_llag113-B8","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.3390\/jcm13185511","article-title":"Escalating threat of drug-resistant human scabies: current insights and future directions","volume":"13","author":"Simonart","year":"2024","journal-title":"J Clin Med"},{"key":"2026072409170814900_llag113-B9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/bjd\/ljad308","article-title":"Failure of scabies treatment: a systematic review and meta-analysis","volume":"190","author":"Mbuagbaw","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026072409170814900_llag113-B10","first-page":"e87","article-title":"Comparison of the effects of ivermectin, permethrin and gamma benzene hexachloride alone and with that of combination therapy for the management of scabies","volume":"29","author":"Dey","year":"2022","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"2026072409170814900_llag113-B11","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.29309\/TPMJ\/2023.30.08.7474","article-title":"Efficacy and safety of oral ivermectin combined with topical permethrin in treatment of scabies","volume":"30","author":"Goraya","year":"2023","journal-title":"Professional Med J"},{"key":"2026072409170814900_llag113-B12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5455\/NJPPP.2025.v15.i2.6","article-title":"A prospective observational comparative study of the effectiveness and adverse effects of 5% topical permethrin and oral ivermectin vs. 5% topical permethrin alone for the treatment of scabies in a tertiary care hospital","volume":"15","author":"Monika","year":"2025","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"2026072409170814900_llag113-B13","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jaad.2019.01.004","article-title":"Efficacy and safety of antiscabietic agents: a systematic review and network meta-analysis of randomized controlled trials","volume":"80","author":"Thadanipon","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2026072409170814900_llag113-B14","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bjd.18943","article-title":"The 2020 International Alliance for the Control of Scabies consensus criteria for the diagnosis of scabies","volume":"183","author":"Engelman","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026072409170814900_llag113-B15","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.12771\/emj.2024.e72","article-title":"Clinical practice guidelines for the diagnosis and treatment of scabies in Korea: part 2","volume":"47","author":"Park","year":"2024","journal-title":"Treatment and prevention. Ewha Med J"},{"key":"2026072409170814900_llag113-B16","doi-asserted-by":"crossref","first-page":"1297337","DOI":"10.3389\/fcimb.2023.1297337","article-title":"Resistance and pseudo-resistance to permethrin: the importance of controlling scabies","volume":"13","author":"Rinaldi","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"2026072409170814900_llag113-B17","first-page":"CD012994","article-title":"Ivermectin and permethrin for treating scabies","volume":"4","author":"Rosumeck","year":"2018","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag113\/67335341\/llag113.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/8\/1442\/67335341\/llag113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/8\/1442\/67335341\/llag113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:17:13Z","timestamp":1784899033000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/8\/1442\/8518714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag113","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,3,13]]}}}